Cargando…

Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter pylori infections. Tegoprazan is mainly metabolized by cytochrome P450 (CYP) 3A4. Considering the therapeutic indications, tegopra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngo, Lien Thi, Lee, Jaeyeon, Yun, Hwi-yeol, Chae, Jung-woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862396/ https://www.ncbi.nlm.nih.gov/pubmed/36678810 http://dx.doi.org/10.3390/pharmaceutics15010182

Ejemplares similares

Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug–Drug Interaction between Rivaroxaban and Carbamazepine in Humans
por: Ngo, Lien Thi, et al.
Publicado: (2023)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
por: Ngo, Lien Thi, et al.
Publicado: (2022)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2023)

Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
por: Oh, Minkyung, et al.
Publicado: (2023)

Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
por: Wei, Zhuodu, et al.
Publicado: (2023)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
por: Marok, Fatima Zahra, et al.
Publicado: (2023)

Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models
por: Ryu, Hyo-jeong, et al.
Publicado: (2021)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Ngo, Lien Thi, et al.
Publicado: (2020)

The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis
por: Tran, Quyen Thi, et al.
Publicado: (2022)

Application of an Inter-Species Extrapolation Method for the Prediction of Drug Interactions between Propolis and Duloxetine in Humans
por: Ngo, Thi Lien, et al.
Publicado: (2020)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
por: Weiss, Johanna, et al.
Publicado: (2016)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of CYP2D6‐Mediated Gene–Drug–Drug Interactions
por: Storelli, Flavia, et al.
Publicado: (2019)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
por: Wendl, Thomas, et al.
Publicado: (2021)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Hwang, Sejung, et al.
Publicado: (2021)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
por: Fuhr, Laura Maria, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
por: Ueno, Takashi, et al.
Publicado: (2021)

A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators
por: Yang, Yiting, et al.
Publicado: (2021)

Fine-tuning of BERT Model to Accurately Predict Drug–Target Interactions
por: Kang, Hyeunseok, et al.
Publicado: (2022)

Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters
por: Barth, Aline, et al.
Publicado: (2023)

Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
por: Park, Chan Hyuk, et al.
Publicado: (2022)

Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects
por: Hwang, Jun Gi, et al.
Publicado: (2019)

Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2022)

Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants
por: Salerno, Sara N., et al.
Publicado: (2020)

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling
por: Fuhr, Laura Maria, et al.
Publicado: (2022)

Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates
por: Otsuka, Yukio, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
por: Marok, Fatima Zahra, et al.
Publicado: (2021)

Fractal Kinetic Implementation in Population Pharmacokinetic Modeling
por: Jung, Woojin, et al.
Publicado: (2023)

PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction
por: Bolleddula, Jayaprakasam, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network
por: Feick, Denise, et al.
Publicado: (2023)

Role of Tegoprazan in Helicobacter pylori Eradication Therapy
por: Lee, Jin
Publicado: (2022)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
por: Min, Jee Sun, et al.
Publicado: (2016)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
por: Xue, Caifu, et al.
Publicado: (2017)

Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor‐Mediated Recycling of HL2351, a Novel Hybrid Fc‐Fused Interleukin‐1 Receptor Antagonist, to Optimize Dosage Regimen
por: Ngo, Lien, et al.
Publicado: (2020)

Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
por: Mulford, Darcy J., et al.
Publicado: (2023)

Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine
por: Marques, Lara, et al.
Publicado: (2023)

Clinical Evaluation of Acetaminophen–Galgeuntang Interaction Based on Population Approaches
por: Tran, Quyen Thi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kabvpk8l8ikj0iodilgr8uie1l